Geode Capital Management LLC Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 8.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 835,790 shares of the company’s stock after buying an additional 62,555 shares during the quarter. Geode Capital Management LLC owned approximately 2.20% of Tarsus Pharmaceuticals worth $27,494,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TARS. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $61,000. Canada Pension Plan Investment Board purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares in the last quarter. FMR LLC boosted its stake in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $202,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ TARS opened at $54.35 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $2.08 billion, a PE ratio of -14.27 and a beta of 1.04. Tarsus Pharmaceuticals, Inc. has a one year low of $18.99 and a one year high of $56.77. The business’s fifty day moving average price is $47.88 and its 200-day moving average price is $35.62.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of recent analyst reports. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.